Swiss Re AG · SIX:SREN

Swiss Re — Investor Presentation (October 2023)

42 slides from Swiss Re's investor presentation, Oct 9, 2023

  1. Slide 1: From Neurotransmission to Neurometabolism: Bipolar Disorder and Epilepsy

    DR. IAIN CAMPBELL. BASZUCKI BRAIN RESEARCH FELLOW IN METABOLIC PSYCHIATRY. THE UNIVERSITY OF EDINBURGH. From Neurotransmission to Neurometabolism: Bipolar Disorder and Epilepsy SWISS RE 09.10.23

  2. Slide 2: Epidemic of Metabolic Syndrome and Diabetes

    Epidemic of Metabolic Syndrome and Diabetes The rise of insulin resistance. Pre-diabetes. 1980 108 Million worldwide with Diabetes Prevalence in adults: 4.7% 2014 422 Million worldwide with Diabetes Prevalence in adults: 8.5% https://www.who.int/news-room/fact-sheets/detail/diabetes

  3. Slide 3: Twin Epidemics: Metabolic Health and Mental Health

    Twin Epidemics: Metabolic Health and Mental Health • WHO estimate that nearly 1 billion people worldwide are now living with a mental disorder. • Mental disorders are the leading cause of disability, causing 1 in 5 years lived with disability. • People with severe mental health conditions die on ave

  4. Slide 4: Epidemic of Metabolic Syndrome and Diabetes

    Epidemic of Metabolic Syndrome and Diabetes ? • Metabolic dysfunction and insulin resistance affects every major organ of the body. Heart: Atherosclerosis • Why would the brain be isolated from this Ovaries: Polycystic ovary syndrome damage? (PCOS) Liver: Non- alcoholic fatty liver disease (NAFLD) A

  5. Slide 5: Energy in the Brain

    Energy in the Brain • The brain is ~2% of human body weight. • Yet it accounts for around 20% of the oxygen and therefore calories burned by the body. • Highly sensitive to energy deficit caused by metabolic dysfunction. • Bipolar disorder is one of the clearest examples of energy dysregulation in s

  6. Slide 6: Research Timeline: Insulin Resistance in the Brain

    Research Timeline: Insulin Resistance in the Brain • The effects of insulin resistance on the peripheral tissues of the body are well researched. • However the effects on neurons in the brain and central nervous system have been under-recognised. 1970 1978 1990s 2000s 2019 Neurons considered Insulin

  7. Slide 7: Research Timeline: Insulin Resistance in Bipolar Disorder

    Research Timeline: Insulin Resistance in Bipolar Disorder 2002 2012 - 2014 2015 2019 2020 Increased prevalence 3X risk of diabetes in T2DM or IR in >50% of First trial of Metformin Improvement in of T2DM in BD BD Patients. IR BD patients. Reduced (Calkin). Better insulin signaling patients independe

  8. Slide 8: Neurotransmission to Neurometabolism

    Neurotransmission to Neurometabolism Neurotransmission Neurometabolism

  9. Slide 9: Neurotransmission & Neurometabolism

    Neurotransmission & Neurometabolism Neurotransmission “This review suggests that the huge research effort based on the serotonin hypothesis has not produced convincing evidence of a biochemical basis to depression.”

  10. Slide 10: How Does Metabolic Dysfunction Express in the Brain?

    HOW DOES METABOLIC DYSFUNCTION EXPRESS IN THE BRAIN? • PI3K/AKT Insulin Signalling plays a significant role. • Regulates brain energy through glucose metabolism and mitochondrial function.

  11. Slide 11: Mechanisms of Action of Lithium from Neurotransmission to Neurometabolism

    MECHANISMS OF ACTION OF LITHIUM FROM NEUROTRANSMISSION TO NEUROMETABOLISM

  12. Slide 12: Lithium Acts on Metabolic Mechanisms in the Brain

    LITHIUM ACTS ON METABOLIC MECHANISMS IN THE BRAIN

  13. Slide 13: Lithium Acts on Metabolic Mechanisms in the Brain

    LITHIUM ACTS ON METABOLIC MECHANISMS IN THE BRAIN

  14. Slide 14: Lithium Acts on Metabolic Mechanisms in the Brain

    LITHIUM ACTS ON METABOLIC MECHANISMS IN THE BRAIN

  15. Slide 15: Lithium Acts on Metabolic Mechanisms in the Brain

    LITHIUM ACTS ON METABOLIC MECHANISMS IN THE BRAIN

  16. Slide 16: Lithium Acts on Metabolic Mechanisms in the Brain

    LITHIUM ACTS ON METABOLIC MECHANISMS IN THE BRAIN

  17. Slide 17: Lithium Acts on Metabolic Mechanisms in the Brain

    LITHIUM ACTS ON METABOLIC MECHANISMS IN THE BRAIN

  18. Slide 18: Lithium Acts on Metabolic Mechanisms in the Brain

    LITHIUM ACTS ON METABOLIC MECHANISMS IN THE BRAIN

  19. Slide 19: Lithium and Insulin Signalling

    LITHIUM AND INSULIN SIGNALLING

  20. Slide 20: Lithium and Insulin Signalling

    LITHIUM AND INSULIN SIGNALLING

  21. Slide 21: What Is Insulin Resistance in the Brain?

    WHAT IS INSULIN RESISTANCE IN THE BRAIN? “We found the therapeutic effect of Lithium in Bipolar Disorder Lithium Responsive patients was associated with Akt signalling and confirmed that an Akt activator mimics Lithium.”

  22. Slide 22: Takeaways

    TAKEAWAYS • Metabolic dysfunction (insulin resistance, type 2 diabetes…) is highly prevalent in people with serious mental illness (SMI). • It is increasingly apparent that metabolic dysfunction in the brain plays a significant, if not primary role in causing SMI. • People with SMI have 2-3 X risk o

  23. Slide 23: Bipolar Disorder and Epilepsy

    Bipolar Disorder and Epilepsy Shared Mechanisms and Medications Anti-seizure Medications Ketogenic Diet Carbamezapine, valproate, Metabolic therapy. 13 RCTs in Epilepsy. lamotrigine. >100 years of clinical use. Pilot studies in bipolar disorder. Episodic Occurrence Co-morbidity Heightened activity A

  24. Slide 24: Bipolar Disorder and Epilepsy

    Bipolar Disorder and Epilepsy Shared Mechanisms and Medications Anti-seizure Medications Ketogenic Diet Carbamezapine, valproate, Metabolic therapy. 13 RCTs in Epilepsy. lamotrigine. >100 years of clinical use. Pilot studies in bipolar disorder. Episodic Occurrence Co-morbidity Heightened activity A

  25. Slide 25: Bipolar Disorder and Epilepsy

    Bipolar Disorder and Epilepsy Shared Mechanisms and Medications Anti-seizure Medications Ketogenic Diet Carbamezapine, valproate, Metabolic therapy. 13 RCTs in Epilepsy. lamotrigine. >100 years of clinical use. Pilot studies in bipolar disorder. Episodic Occurrence Co-morbidity Heightened activity A

  26. Slide 26: Bipolar Disorder and Epilepsy

    Bipolar Disorder and Epilepsy Shared Mechanisms and Medications Anti-seizure Medications Ketogenic Diet Carbamezapine, valproate, Metabolic therapy. 13 RCTs in Epilepsy. lamotrigine. >100 years of clinical use. Pilot studies in bipolar disorder. Episodic Occurrence Co-morbidity Heightened activity A

  27. Slide 27: Bipolar Disorder and Epilepsy

    Bipolar Disorder and Epilepsy Shared Mechanisms and Medications Anti-seizure Medications Ketogenic Diet Carbamezapine, valproate, Metabolic therapy. 13 RCTs in Epilepsy. lamotrigine. >100 years of clinical use. Pilot studies in bipolar disorder. Episodic Occurrence Co-morbidity Heightened activity A

  28. Slide 28: Bipolar Disorder and Epilepsy

    Bipolar Disorder and Epilepsy Shared Mechanisms and Medications Anti-seizure Medications Ketogenic Diet Carbamezapine, valproate, Metabolic therapy. 13 RCTs in Epilepsy. lamotrigine. >100 years of clinical use. Pilot studies in bipolar disorder. Episodic Occurrence Co-morbidity Heightened activity A

  29. Slide 29: Bipolar Disorder and Epilepsy

    Bipolar Disorder and Epilepsy Shared Mechanisms and Medications Anti-seizure Medications Ketogenic Diet Carbamezapine, valproate, Metabolic therapy. 13 RCTs in Epilepsy. lamotrigine. >100 years of clinical use. Pilot studies in bipolar disorder. Episodic Occurrence Co-morbidity Heightened activity A

  30. Slide 30: Systematic Review: Brain Imaging Biomarkers in Bipolar Disorder

    Systematic Review: Brain Imaging Biomarkers in Bipolar Disorder • Systematic review indicates that brain glutamate level is consistently increased in BD. (Chabert et al., 2022) • Reduction in glutamate, glutamine, and Glx (glutamate+glutamine) in BD patients is considered a marker of response to pha

  31. Slide 31: Neurotransmission to Neurometabolism

    Neurotransmission to Neurometabolism Neurotransmission Neurometabolism

  32. Slide 32: Review: Epilepsy Blood Biomarkers

    Review: Epilepsy Blood Biomarkers “Changes in Glu, Alanine, aspartate lactate and citrate and glutamate are most common in metabolism. the serum of people with epilepsy.” D-Glutamine and D- glutamate metabolism [PMID: 29782966]

  33. Slide 33: Review: Epilepsy Blood Biomarkers

    Review: Epilepsy Blood Biomarkers • Ketosis appears to downregulate glutamate metabolism in favour of GABA, promoting a reduced excitatory state in the brain. • It has been suggested that this is an important mechanism of action in seizure reduction. • Could this also explain some of the mood stabil

  34. Slide 34: MRS Edinburgh Pilot Study of a Ketogenic Diet For Bipolar Disorder

    Magnetic Resonance Spectroscopy (MRS) Edinburgh Pilot Study of a Ketogenic Diet For Bipolar Disorder • Glx decreased from baseline by 9.22% in the ACC (p<0.02) • Glx decreased from baseline by 13.13% in the PCC (p<0.001)

  35. Slide 35: Glutamate as a Metabolic Fuel Source

    Glutamate as a Metabolic Fuel Source • Research in bipolar disorder has primarily focused on the role of glutamate as an excitatory neurotransmitter. • However, the role of glutamate as a metabolic substrate was an original focus of Hans Krebs research throughout the 1960s. • Focus of research shift

  36. Slide 36: Energy Dysregulation in BD

    Energy Dysregulation in BD 1. Increased lactate, indicating impaired glucose metabolism. 1. Campbell (2023). Hyperglycolysis and Glutaminolysis in Bipolar Mania. Molecular Psychiatry (In Press).

  37. Slide 37: Energy Dysregulation in BD: Ketones as Alternative Fuel

    1. Increased lactate indicating, impaired glucose metabolism. 1. 1. 2. Ketones act as an alternative 2. fuel source to restore energy Ketones (ATP). Campbell (2023). Hyperglycolysis and Glutaminolysis in Bipolar Mania. Molecular Psychiatry (In Press).

  38. Slide 38: Energy Dysregulation in BD: Glutamate as Energy Source

    1. Increased lactate indicating, impaired glucose metabolism. 2. Ketones act as an alternative 1. 2. fuel source to restore energy Ketones (ATP). 3. Glutamate can also be used as a significant alternative 3. energy source in neurons. Campbell (2023). Hyperglycolysis and Glutaminolysis in Bipolar Man

  39. Slide 39: Energy Dysregulation in BD: Aspartate

    1. Increased lactate indicating, impaired glucose metabolism. 2. Ketones act as an alternative 1. 2. fuel source to restore energy Ketones (ATP). 3. Glutamate can also be used as a significant alternative 3. 4. Aspartate energy source in neurons. 4. Aspartate participates in the transamination react

  40. Slide 40: Energy Dysregulation in BD: Ketones and GABA

    1. Increased lactate indicating, impaired glucose metabolism. 2. Ketones act as an alternative fuel 1. source to restore energy (ATP). 2. Ketones 5. 3. Glutamate can also be used as a significant alternative energy source in neurons. 4. Aspartate is participates in the transamination reaction conver

  41. Slide 41: Summary

    Summary • Bipolar Disorder shares anti-seizure medications with epilepsy. • A metabolic therapy for epilepsy (ketogenic diet) is now showing indications of beneficial effects in bipolar disorder. • Ketosis causes a shift from excitatory brain activity toward inhibitory activity by reducing glutamate

  42. Slide 42: Thank you

    Thank you Becky, Skye and Atholl Jan, Dave, Matthew and the Baszucki Brain Research Fund John Schoonbee. Andreas Obrist. Swiss Re. Nicole Needham, Helen Grossi, Ivana Kamenska, Saturnino Luz, Shane Sheehan, Gerard Thompson, Michael J Thrippleton, Melissa C Gibbs, Joana Leitao, Tessa Moses, Karl Burg

Swiss Re — Investor Presentation (October 2023) on 6ix